Adherencia y fallo terapeútico en el seguimiento de una muestra de sujetos VIH+algunas hipótesis desde la psicología

Referencias bibliográficas

• Ader, R., Cohen, N. y Felten, D. (1995). Psychoneuroinmunology: interactions between the nervous system and the immune system. Lancet, 345, 99-103.
• Anastos, K., Kalish, L., Hessol, N., Weiser, B. , Melnick, S., Burns, D., Delapenha, R., DeHovitz, J., Cohen, M., Meyer, W., Bremer, J. y Kovacs, A. (1999 ). The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected woman : results of the women’s interagency HIV study. AIDS , 13, 1.717- 1.726.
• Bower, J., Kemeny, M., Taylor, S. y Fahey, J. (1998). Cognitive processing, discovery of meaning, CD4 decline, and AIDS-related mortality among bereaved HIV-seropositive men. Journal of Consulting and Clinical Psychology, 66, 979-986.
• Catalán, J. (1997). The Psychiatry of HIV infection. Advances in Psychiatric Treatment, 3, 17-24.
• Ciesla, J. y Roberts, E. (2001). Meta-analysis of the relationship between HIV infection and risk for depressive disorders. American Journal of Psychiatry, 158, 725-30.
• Cozzi Lepri, A., Katzenstein, T., Ullum, H., Phillips, A., Skinhoj, P., Gerstoft, J. y Pedersen, B. (1998). The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS, 12, 1.639-1.643.
• D’Arminio, A., Testori, V., Adorni, F., Castelnuovo, B., Bini, T., Testa, L., Moscatelli, G., Chiesa, E., Rusconi, S., Abeli, C., Sollima, S., Músico, M., Meroni, L., Galli, M. y Morono, M. (1999). CD4 cell counts at the third month of HAART may predict clinical failure. AIDS, 13, 1.669- 1.676.
• Deeks, S., Barbour, J., Martin, J., Swanson, S. y Grant, R. (2000). Sustained CD4+ T cell response after virologic failure of protease inhibitorbased regimens in patients with human immunodeficiency virus. Journal of Infectious Diseases, 18, 946-53.
• Delmas, M., Jadand, C., De Vicenzi, I. et al. (1997). Gender differences in CD4+ cell counts persist after HIV-1 infection. AIDS, 11, 1.071-1.073.
• Dinan, T. (1999). The physical consequences of depressive illness. British Medical Journal, 318, 826.
• Esterling, B., Kiecolt-Glaser, J., Bodnar, J. y Glaser, R. (1994). Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults. Health Psychology, 13, 291-298.
• Evans, J., Nims, T., Cooley, J. et al. (1997). Serum levels of virus burden in early stage of HIV-1 disease in women. Journal of Infectious Diseases, 175, 795-800.
• Farzadegan, H., Hoover, D., Astemborski, J. et al. (1999). Sex differences in HIV-1 viral load and progression to AIDS. Lancet, 35, 1.510-1.514.
• Gibson, D., McCusker, J. y Chesney, M. (1998). Effectiveness of psychosocial interventions in preventing HIV risk behaviour in injecting drug users. AIDS, 12, 919-929.
• Glaser, R., Rabin, B., Chesney, M., Cohen. S. y Natelson, B. (1999). Stress-Induced Immunomodulation. Implications for infectious diseases? JAMA, 281, 2.268-2.270.
• Gonzalez, A. y Everall, I.P. (1998). Lest we forget: neuropsychiatry and the new generation anti-HIV drugs. AIDS, 12, 2.365-2.367.
• Gordillo, V., del Amo, J., Soriano, V. y González-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1.763-1.769.
• Grabar, S., Le Moing, V., Goujard, C. et al. (2000). Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Annals of Internal Medicine, 133, 401-11.
• Gulick, R.M. (2000). Assessing the benefits of antiretroviral therapy. Annals of Internal Medicine, 133, 471-473.
• Haubrich, R., Little, S., Currier, J., Forthal, D., Kemper, C., Beall, G., Johnson, D., Dube, M., Hwang, J. y McCutchan, J. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virological and immunologic response. California Collaborative Treatment Group. AIDS, 13, 1.099-1.107.
• Holzemer, W., Corless, I., Nokes, K., Turner, J., Brown, M., Powell-Cope, G., Inouye, J., Henry, S., Nicholas, P. y Portillo, C. (1999). Predictors of self-reported adherence in persons living with HIV disease. Aids Patient Care STDS, 13, 185-197.
• Ickovics, J.R. (1997). Measures of adherence. Adherence to New HIV Therapies: A Research Conference. Washington, DC. November.
• Judd, F y Mijch, A. (1996). Depressive symptoms in patients with HIV infection. Australian New Zealand Journal of Psychiatry, 30, 104-109.
• Junghans, C., Ledergerber, B., Chan, P. et al. (1999). Sex differences in HIV-1 viral load and progression to AIDS. Lancet, 353, 589.
• Kaplan, A., Golin, C., Beck, K., Liu, H., Hays, R., Ickovics, J. y Wenger, N. (1999). Adherence to Protease Inhibitor Therapy and Viral Load (Abstract 97). 6th Conference on Retroviruses and Opportunistic Infections, Chicago.
• Kaufmann, D., Pantaleo, G., Sudre, P. y Telenti, A. (1998). CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) (Letter). Lancet, 351, 723-4.
• Kleeberger, C., Phair, J., Strathdee, S. et al. (2001). Determinants of heterogeneous adherence to HIV Antiretroviral therapies in the Multicenter AIDS Cohort Study. Journal of AIDS, 26, 82-92.
• Leserman, J., Petitto, J.M., Perkins, D., Folds, J., Golden, R. y Evans D. (1997). Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Archives of General Psychiatry, 54, 279-285.
• Low-Beer, S., Chan, K., Yip, B. et al.( 2000). Depressive symptoms decline among persons on HIV protease inhibitors. Journal of AIDS, 23, 295-301.
• Lucas,G.,Chaisson,R. y Moore,R. (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81-7.
• Lyketsos, C., Hanson, A., Fishman, M., McHugh, P. y Treisman, G. (1994). Screening for psychiatric morbidity in an medical outpatient clinic for HIV infection: the need for a psychiatric presence. International Journal of Psychiatry and Medicine, 24, 103-113.
• Maini, M., Gilson, R., Chavda, N. et al. (1996). Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Medicine, 73, 27-31.
• Mellors , J., Muñoz, A., Giorgi, J., Margolick, J. , Tassoni, C., Gupta, P. , Kingsley, L ., Todd, J ., Saah, A. , Detels , R., Phair, J. y Rinaldo, C. Jr. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine, 126, 946-954.
• Moroni, M. for ICONA.(1999). Sex differences in HIV-1 viral load and progression to AIDS. Lancet, 353, 859-890.
• Nott K.H, Vedhara, K. y Spickett, G.P. (1995). Psychology, immunology, and HIV. Psychoneuroendocrinology, 20, 451-474.
• Nott, K.H. y Vedhara, K. (1999). Nature and consequences of stressful life events in homosexual HIV-positive men: a review. AIDS Care, 11, 235-243.
• Palella, F., Delaney, K., Moorman, A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853-60.
• Paterson, D., Swindells, S., Mohr, J. et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
• Pehrson, P.O., Lindbäck, S., Lidman, Ch., Gaines, H. y Giesecke, J. (1997). Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS, 11, 1.007-1.012.
• Phillips, A., Eron, J., Bartlett, J. et al. (1996). HIV-1 RNA levels and the development of clinical disease. AIDS, 10, 859-865.
• Powderly, W., Saag, M., Chapman, S., Yu, G., Quart, B. y Clendeninn, N. (1996). Predictors of optimal virological response to potent antiretroviral therapy. AIDS, 13, 1.873-1.880.
• Rabkin, J., Wagner, G. y Rabkin, R. (1999). Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. American Journal of Psychiatry, 156, 101-107.
• Rabkin, J., Wagner, G. y Rabkin, R. (1997). Prevalence and Treatment of depressive disorders in HIV illness. Medscape Mental Health, 2, 1-10.
• Roberts, J., Ciesla, J., Direnfeld, D. y Hewitt, R. (2001). Vulnerability to psychological distress among HIV-positive individuals: the roles of acute stressful life events and neuroticism. Personality and Individual Differences, 30, 241-257.
• Schiaffino, K., Shawaryn, M. y Blum, D. (1998). Examining the impact of illness representations on psychological adjustment to chronic illnesses. Health Psychology, 17 , 262-268.
• Soloway, B. y Friedland, G. (2000). Antiretroviral failure: a biopsychosocial approach. AIDS Clinical Care, March..
• Staszewski, S., Miller, V., Sabin, C., Schlecht, C., Gute, P., Stamm, S., Leder, T., Berger, A., Weidemann, E., Hill, A. y Phillips, A. (1999). Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS, 13, 951-956.
• Stone, V., Clarke, J., Lovell, J. et al. (1998). HIV/AIDS patients’ perspectives on adhering to regimens containing protease inhibitors. Journal of General Internal Medicine, 13, 568-93.
• Stone, V. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clinical Infectious Diseases, 33, 865-72.
• Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J., Margolick, J., Lyles, C., Nelson, K., Smith, D., Holmberg, S. y Farzadegan, H. (1998). Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA, 279, 35-40.
• Yerly, S., Perneger, T., Hirschel, B., Dubuis, O., Matter, L., Malinverni, R., Furrer, H. y Perrin, L. (1998). A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss HIV Cohort Study. Archives of Internal Medicine, 158, 247-252.
• Zorrilla, E., McKay, J., Luborsky, L. y Schmidt, K. (1996). Relation of stressors and depressive symptoms to clinical progression of viral illness. American Journal of Psychiatry, 153, 626-635.